KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Accumulated Depreciation & Amortization: 2011-2025

Historic Accumulated Depreciation & Amortization for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $2.7 million.

  • Halozyme Therapeutics' Accumulated Depreciation & Amortization rose 3.85% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2.34%. This contributed to the annual value of $10.3 million for FY2024, which is 7.21% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $2.7 million for Q3 2025, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $2.9 million during Q4 2023, with a 5-year trough of $700,000 in Q3 2021.
  • In the last 3 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization had a median value of $2.7 million in 2025 and averaged $2.7 million.
  • In the last 5 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization dropped by 18.00% in 2021 and then skyrocketed by 231.06% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $776,000 in 2021, then soared by 231.06% to $2.6 million in 2022, then climbed by 12.88% to $2.9 million in 2023, then dropped by 7.24% to $2.7 million in 2024, then increased by 3.85% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.7 million during Q1 2025.